CYP19A1 and neoplasm: ERα and ERβ are present ubiquitously in human NSCLC cell lines (41-JTO), and preclinical studies show that the combination of TKIs, such as gefitinib and erlotinib, and fulvestrant or aromatase inhibitor demonstrated a synergic anti-tumor effect in vivo and in vitro (9).